Found 5 matching trials
Long-term Study of Semapimod (CNI-1493) for Treatment of Crohn's Disease
PHASE2CNI-1493-CD05 is an open-label extension study of CNI-1493-CD04. In the CD0...
Location
University of California, San Francisco
CNI-1493 for Treatment of Moderate to Severe Crohn's Disease
PHASE2The purpose of this study is to determine whether CNI-1493 is safe and effe...
Location
Institute of Healthcare Assessment
Extension Study of Semapimod 60 mg IV x 3 Days
PHASE2Study CNI-1493-CD06 is an open, single-arm extension studies to CD03 and CD...
Location
Northwestern University
Single Ascending Dose Study of Oral CPSI-2364 (Semapimod)
PHASE1This study will be conducted in healthy male or female subjects using a dou...
Semapimod for Treatment of Moderate to Severe Crohn's Disease 1 or 3 Days' Treatment Versus Placebo
PHASE2Assessment of the number of days' treatment with semapimod necessary for ef...
Location
Institute of Healthcare Assessment